A Phase II Study Using Talimogene Laherparepvec as a Single Agent for Inflammatory Breast Cancer (IBC) or Non-IBC Patients With Inoperable Local Recurrence
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 01 Aug 2016 Planned primary completion date changed from 1 Jul 2021 to 1 Aug 2021.
- 01 Aug 2016 Status changed from not yet recruiting to recruiting.
- 27 Apr 2016 Planned primary completion date changed from 1 Mar 2021 to 1 Jul 2021.